Many of our cardiologists are involved in major national research trials, participating in both drug studies and device studies to determine more effective cardiac care and treatments. From the latest pharmaceutical treatments to such advanced equipment as the distal protection device, we study new compounds and devices to determine how we can improve the lives of our cardiac patients. In addition, we often follow these same patients for several years to measure long-term effects and track any adverse events. This enables us to determine the safest, most effective treatment regimens for our cardiac patients.

SYNTAX “Synergy between PCI with Taxus and Cardiac Surgery.”

SHINE “A Randomized Dose Ranging Study of Hexadecasaccharide including active Control, in Patients with Unstable Angina or Non-ST-segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention.”

TRITON “A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention/TIMI-38”

TIMI 37a “A Phase II Randomized, Placebo Controlled, Single-Blind, Multi-Center, Dose-Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single Intravenous Administration of INO-1001 in Subjects with STEMI Undergoing Primary Percutaneous Coronary Intervention.”

ARRIVE 2 “TAXUS Post Approval Registry:  A Multi-center Safety Surveillance Registry.”

PERISCOPE “A Double-Blind, Randomized Comparator- Controlled Study in Subjects with Type II Diabetes Mellitus Comparing the Effects of Pioglitazone HCI versus Glimepiride on the Rate of Progression of Atherosclerotic Disease as Measured by Intravascular Ultrasound.”

ACUITY TRAIL “A randomized comparison of Angiomax (bivalirudin) versus heparin (unfractionated heparin or enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation.”

CETP IVUS “A Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared with Atorvastatin Alone, in Subjects with Angiographically Documented Coronary Heart Disease.”

BIOMARIN “A Phase 2a, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Efficacy of 6R-BH4 in Subjects with Sickle Cell Disease.”

MAPP “The primary objective of this Phase 3 study is to compare the efficacy and safety of MAP0004 to placebo in adult migraineurs for a single migraine.  The secondary objective is to initiate a long-term safety database (up to 6 and /or 12 months of exposure) of MAP0004.

GENENTECH “Peforming echocardiograms to assess LVEF for patient undergoing treatment with an investigational drug for metastatic breast cancer.”